Locally Advanced/Metastatic SACT | Right Decisions

Right Decisions
Scottish Cancer Network: Clinical Management Pathways
Lung Cancer
Systemic Anti-Cancer Therapy (SACT)
Back
Non-Small Cell Lung Cancer (NSCLC)
Locally Advanced/Metastatic SACT

Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Please note: the inclusion of locally advanced is for patients that have Stage III NSCLC but are not suitable for radical treatment with either surgery or radiotherapy.

Throughout the patient pathway, consideration should be given to patient preference, performance status and other relevant patient factors.

Patient eligibility and suitability for available clinical trials should be considered and discussed with individual patients as appropriate.

Author

Nicola Steele (on behalf of SACT subgroup)

Reviewer

John Maclay

Date of creation

Updated

20/09/2023

16/04/2024

Version number

1.1

Review Date

20/09/2026

Contact

nss.scottishcancernetwork@nhs.scot

The printing of visual pathways is strongly discouraged, due to the inability to print all relevant information contained within and behind the pathways. Any user choosing to do so must acknowledge that the information may be incomplete and that essential context may be missing from a printed or reproduced pathway.

Non-Squamous NSCLC

Squamous NSCLC